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INTRODUCTION
The materials requirements for composites for biomedi-
cal applications include all the usual mechanical property
requirements for general engineering composites of stiff-
ness, strength, toughness, and so on. However, there are
additional biological requirements, the materials have to
be biocompatible, that is, not produce a disadvantageous
biological response in the required application [1,2] includ-
ing in the case of degradable materials the degradation
products must also be biocompatible. An additional desir-
able property is that the material should be bioactive, that
is, it should produce a beneficial response in the appropri-
ate application [1,2]. Bioactive means that the body’s cells
react beneficially with thematerial, and in the case of hard
tissue applications, the bone cells, instead of producing a
layer of fibrous tissue between the patient’s own bone and
the implant, produce new bone directly on the implant.
This direct bone–implant contact leads to a mechanically
stronger interface and thus a stronger and more durable
bone–implant structure.
From a mechanical point of view, bone has two major
functions, to provide a stiff skeleton against which the
muscles can contract to provide locomotion and secondly
to protect the major organs such as the brain, protected
by the skull, and the heart and lungs, protected by the
rib cage (Fig. 1). Biologically, bone provides a store of cal-
cium and phosphate ions that are essential for biological
function, while the marrow is the source for red and white
blood cells [3]. At the macroscopic scale, there are two
types of bone. The first type of bone is known as cortical,
which is a nearly solid material, making up the outer
surfaces of all bones, with a porosity of <3% in normal
people [3]. The second type of bone is porous, is called
either cancellous or trabecular bone, being a foam of bone
made up of small struts called trabeculae. Cancellous bone
is found throughout the middle of bones such as the ribs
and the skull and at the end of long bones below the joint
surface. The porosity ranges from 30% to 90%, depending
on the position in the body, age, and activity level of the
person. Both cortical and cancellous bones become more
porous with age and conditions, such as osteoporosis that
particularly affects postmenopausal women. At the struc-
tural and microstructural levels, cortical and cancellous
bones have different structures in the form of osteons in
cortical bone and trabeculae in cancellous bone. At the
nanostructural level, all bone material is a composite of
collagen, a natural polymer, filled with a calcium phos-
phate mineral, thus a particulate-reinforced composite.
There are three major types of bone cells, osteoblasts that
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deposit new bone, osteocytes that are present throughout
mature bone, and osteoclasts that resorb old and damaged
bone. The properties of bone as a composite material are
discussed in greater detail in the article titled Composite
Scaffolds for Bone Tissue Regeneration elsewhere in
this handbook. Hard tissue implants could either be going
into or on to the shaft of bones and, thus, can contact
cortical or cancellous bone or both. Young’s modulus of
cortical bone is 7–25GPa, while that for cancellous bone
is 100–1000MPa and their strengths are 50–150 and <50
MPa, respectively; all these mechanical properties depend
on age, gender, activity level, and pathology in addition
to the usual composite mechanical testing parameters of
orientation and test velocity [4,5].
The major uses of hard tissue implants are as joint
replacement to treat problems such as osteoarthritis, in
fracture fixation where the bone ends need to be held sta-
tionary relative to each other until the fracture has healed,
filling of bony defects, such as after a tumor has been
removed, and, the newest application, tissue engineering.
For applications such as joint replacement, the material
needs to retain its properties for the rest of the patient’s
life, while for fracture fixation or tissue engineering scaf-
folds, the material should degrade once the function of the
implant has been taken over by newly formed tissue [1,2].
In tissue engineering, cells are removed, usually from the
patient themselves, grown up in the laboratory to increase
the number of biologically active cells and then seeded
into a scaffold that is then implanted back into the patient
[6]. The scaffold material needs to be an open-celled foam
of a degradable material so that the cells can be dis-
tributed throughout the scaffold material, body fluids can
flow through to the cells to provide nutrients and remove
waste products, and finally the scaffold material needs to
degrade at the same rate as new material is produced
by the body. The earliest composite implants used in the
1970s and 1980s were nondegradable, but in the last 30
years, degradable materials have been investigated and
been used clinically.
Considering composites that have been developed
specifically for biomedical applications, a range of matrix
materials and fillers have been tested individually and
been shown to be biocompatible. However, virtually no
coupling agents have undergone biocompatibility testing
and, therefore, most biomedical composites avoid the
use of coupling agents and rely solely on mechanical
interlocking to bond the filler and the matrix. Currently,
most composites used in biomedical applications are
either particulate-filled polymers or drawn polymer fibers
in a polymer matrix; a few more recent applications
use bioactive glass (BG) fibers. Most polymers used for
the matrix phase are biocompatible, but only a few are
bioactive and being polymers all are lower modulus than
cortical bone. However, many calcium phosphate ceramic,
glass, or glass–ceramic fillers are bioactive, particularly
in bony applications, as well as having higher moduli;
thus, their use should increase stiffness and bioactivity of
the composite and can increase the strength.
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Figure 1. Section through a proximal femur (thigh bone) show-
ing cortical (lower walls) and cancellous bone (center of the
femoral head).
The testing of biomedical composites includes the usual
mechanical tests to assess the mechanical behavior of the
material including fatigue tested at a frequency and in
an environment that models the human body. Addition-
ally, there are four groups of biological testing required
with increasing levels of complexity and cost, two types of
in vitro tests that are performed in the laboratory, in vivo
tests performed in animals, and finally clinical trials. The
first of the in vitro tests is soaking in a solution that
mimics the appropriate body fluid to assess both how the
material will break down after implantation and how the
material’s properties change with time. While accelerated
tests can be performed at raised temperature, most bioma-
terials testing is performed at body temperature (37◦C),
owing to the sensitivity of polymers to temperature effects,
particularly in terms of their degradation behavior. In
many applications, saline is the appropriate solution, but
for potentially bone-bioactive materials, a simulated body
fluid (SBF), such as that developed by Kokubo et al. [7]
that is chemically very close to blood plasma, will be used.
If a bone-bioactive material is placed in one of these solu-
tions, a layer of apatite will be deposited on the surface,
as would happen on implantation in the body, whereas
a bioinert material does not produce this response. The
second type of in vitro test uses cells and either the cells
are grown in an elutant of the material, produced by soak-
ing the material in a cell culture medium, or the cells are
grown on the material surface. The elutant tests are to
check for cytotoxicity, while the culturing of cells on the
material is to assess the direct interaction of cells with the
material, including how the cells attach to the material
and whether their grown rate is increased or decreased by
this contact with the material. The type of cell grown will
depend on the potential application of the material and for
bone applications is commonly either a line of bone cancer
cells or bone cells taken from human hip joints at total hip
replacement. Assuming that the new material has passed
these tests as being biocompatible and even bioactive the
last set of tests before human use is implantation in an
animal, thus is know as in vivo testing. Finally, a clinical
trial will be performed before the new material or device
is released for general use. The costs of both in vivo test-
ing and clinical trials are high and are highly controlled
by national regulations. In the United States, approval is
given by the Food and Drug Administration (FDA), while
in Europe, approval is shown by a CE mark [8].
PRODUCTION OF BIOACTIVE COMPOSITES
All the techniques used for conventional composite mate-
rials production and polymerization are applicable to
biomaterials production, although the number of potential
matrix and filler materials are constrained by biocom-
patibility requirements. Biomedical composites based on
thermoplastics and thermosets can be produced by conven-
tional composite production methods such as compound-
ing, extrusion, and injection molding and the application
of preimpregation to produce ‘‘prepregs.’’ In the production
of fiber-reinforced composites, techniques such as filament
winding have been used to produce devices including arti-
ficial intervertebral discs [9,10]. Selective laser sintering
of both powders of composite materials and of the individ-
ual phases has been performed to produce custom built
porous materials [11–13].
Nondegradable Bioactive Composites
The first composite material to enter clinical use was
carbon-fiber-reinforced epoxy; it is extremely strong and
light, with an elastic modulus close to that of bone, radi-
olucent, that is, allows X-rays to pass through it, enabling
the bone below the implant to be monitored and most
importantly biocompatible [14]. This material was used
clinically as fixation fracture plates [15–17]. The devices
were manufactured using layup of prepreg with compres-
sion molding to produce plates with fiber orientations of
0◦ in the outer layers and ±45◦ in the internal layers. The
plates had a bending stiffness about 20% of the equiva-
lent stainless steel plates, but showed 60% higher fatigue
limit and angulation at failure. The plates were used to
treat forearm fractures in 29 patients. The results showed
that the patients treated with the carbon-reinforced epoxy
composite plates were able to use their arms earlier in
comparison with patients treated with the same size
and shape metal plates. All the implants were removed
after the fracture had healed. In another study, semirigid
carbon-fiber-reinforced epoxy plates were used for cranio-
plasty, that is, the repair of defects in the skull, with a
mean follow-up period of 3.3 years in five elderly female
patients with severe osteoporosis and highly restricted
mobility [18]. These patients had no adverse reactions to
the plate, again supporting the use of carbon-reinforced
epoxy in bone fixation. However, the major problem with
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carbon-fiber epoxy composites is that the implants cannot
be bent to fit the patient in the operating theater, unlike
the equivalent metal plates where plastic deformation is
possible, thus restricting the use of these composite plates
to the human forearmwhere the bones are close to straight
or to either preformed or low modulus implants as were
used in the skull.
A different approachwas takenBonfield and colleagues,
who proposed the use of high density polyethylene (HDPE)
reinforced with hydroxyapatite (HA). Their philosophy
was the ‘‘bone-analog’’ concept, that is, to produce a mate-
rial with similar mechanical and biological properties to
bone, consider the natural material, and try to repro-
duce it. In HA–polyethylene (PE), the bone mineral was
modeled by the HA and PE replaced the collagen, the
HA providing stiffness and bioactivity, while the PE was
responsible for ductility and toughness; at 40 vol% HA,
the stiffness had increased from 0.94 to 4.29GPa [19,20].
The first clinical application of this composite was as
orbital floor implants and showed good biological responses
[21,22]. Thereafter, the 40 vol% HA composite, HAPEX™,
was used as the shaft of middle ear implants with the pos-
sibility of the supporting bone bonding with the HAPEX
shaft, generating long-term stability of the implant; the
high density of the composite was expected to improve the
sound transfer through the implant shaft and the shaft
could easily be trimmed intraoperatively to fit the indi-
vidual patient. Goldenberg and Driver [23] reviewed the
implant in 233 patients and found that the success rate
was 56.8% defined by good hearing with only 5.3% implant
extrusion occurred and 7.7% slippage. Meijer et al. [24],
when reviewing some of the implants removed owing to
reoccurrence of the original clinical problem, found good
tissue cover, indicating better tissue acceptance than that
occurred with previous implants of the same design, but
manufactured using either Proplast or Plastipore.
Various attempts have been made to increase the
mechanical properties of HAPEX. HAPEX was manu-
factured by compounding extrusion of spray-dried HA
particles in HDPE. Joseph et al. [25,26] varied the molecu-
lar weight of the PE to produce an injection molding grade
of HAPEX and found that increasing both the filler con-
tent of the composite and the molecular weight of the PE
increased the viscosity of the melted composite. A similar
effect was seen when using the nonsintered HA used in
HAPEX rather than a sintered HA powder with the same
mean particle size, but a specific surface area one-tenth of
the nonsintered grade.
Ward and Bonfield and their colleagues attempted to
produce HAPEX with higher and anisotropic mechan-
ical properties by using hydrostatic extrusion [27,28].
Optimization of the extrusion ratio leads to a maximum
flexural stiffness of 9GPa and strength of 91MPa in the
longitudinal direction, although some slight reductions
in the transverse properties were seen at the highest
extrusion ratios.
A different approach to increase the mechanical
properties was using very stiff drawn HDPE fibers as an
additional filler in HA/HDPE composites [29,30]. They
reported increases in stiffness and strength values to
17GPa and 113MPa respectively, suggesting that the
mechanical performance of the composite can be further
increased. Alternatively, Reis and colleagues [31–33]
used the shear-controlled orientation injection molding
(SCORIM) method by applying a macroscopic shear stress
field at the melt/solid interface of the polymer during
the molding cycle. This molding technique produced
anisotropy in the HDPE and HDPE/HA composite and
yielded stiffness values between 5 and 7GPa. None of
these higher modulus and anisotropic composites have
progressed through to clinical applications, probably
because of the complexity of applying the processing
methods in a ‘‘clean’’ materials production environment
as would be needed for clinical applications. This problem
of ensuring that no contaminants enter during the pro-
duction of medical grade composites has been a problem
for many investigators.
Since these studies other authors have produced
mineral-reinforced polymer composites, using either HA
or to give a degradable mineral filler using tricalcium
phosphate (TCP). HA (Ca10(PO4)6(OH)2) is stoichiometric
version of bone mineral and, depending of the degree of
crystallinity, either does not degrade or only degrades
slowly, while TCP (Ca3(PO4)2) degrades more quickly in
the body and is commonly used as a filler with the aim
of increasing bone repair due to the supply of calcium
and phosphate ions. The degradation rate of TCP depends
on whether it has the α- or β-crystallographic structure
and increasing the crystallinity decreases the degradation
rate. Polyetheretherketone (PEEK) is a high performance
engineering polymer with good biocompatibility in vivo.
Bioactive PEEK composites are produced usually by
compounding of the polymer with calcium phosphates
including HA or β-TCP. Petrovic et al. [34] studied
bioactive PEEK filled with 5–40% β-TCP and reported
proliferation normal human osteoblasts onto the compos-
ite. The finding leads to conclusion that the pure PEEK
was nontoxic and has good biological interactions. Abu
Bakar et al. [13] studied the use of HA/PEEK composites
for bone substitution implants. The PEEK was reinforced
with smooth thermal sprayed spherical HA particles via
compounding followed by injection molding. The stiffness
increased with the reinforcement volume up to the maxi-
mum tested of 40 vol% HA particles from 2.8 to 16.0GPa;
however, the ductility decreased and the strength reduced
from 69 to 45.4MPa. These composite were also laser
sintered to produce porous implants that were tested in
vivo and showed good biological responses. Weng et al. [35]
successfully produced nanoscale composites of PEEK–HA
with 5 and 15 vol% of nanosized HA. The results showed
the tensile strength increased with additional of the filler
up to 15 vol%. The maximum strength was 93MPa at 5
vol% and microscopic study showed that the HA particles
are well bonded to the matrix.
Hao and colleagues [36–39] compounded 4μm
diameter HA particles into polyamide at 30 vol% or
PE at 20 vol% and then selectively laser-sintered (SLS)
powders of these composites to produce samples for
mechanical testing and cell culture studies. The SLS
process produced interconnecting open-celled pores and
optimization of the process lead to material with flexural
modulus measured using dynamic mechanical analysis
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(DMA) up to 560MPa at 37◦C. Cell seeding with an
osteoblast cell line showed the material to be bioactive,
with mineralization occurring after 28 days in culture
without the addition of dexamethazone, which is normally
added to tissue culture medium to get cultured osteoblasts
to mineralize.
Degradable Bioactive Composite Production
Biodegradable polymers and composites are used where
the implant is no longer needed once the bone has healed,
such as fracture healing and tissue engineering scaf-
folds. The most widely studied synthetic biodegradable
polymers for hard tissue applications are the polyesters
including poly(lactic acid) (PLA), poly(glycolic acid) (PGA),
poly(hydroxybutyrate) (PHB), poly(lactic-co-glycolic acid)
(PLGA), and poly(ε-caprolactone) (PCL). Degradation
mechanisms of these polymers include surface and bulk
erosion and the polymers have a range of degradation
rates in the body. In the case of PLA, the polymer has two
stereotactic forms known as L and D. The L form produces
a highly crystalline bulk polymer with slow degradation
rates, whereas the D form is less organized and thus
has a faster degradation rate [40]. PHB copolymerizes
with polyhydroxyvalerate (PHV) and increasing the PHV
content decreases the stiffness, but increases the ductility
of the bulk polymer. The processing route can be tailored
to enhance the mechanical properties of the specimens.
Poly-L-lactic acid (PLLA) usually has tensile strength
and modulus of 50–70MPa and 3–5GPa, respectively,
while PGA has a tensile modulus of 6–7GPa and tensile
strength of 60–100MPa. To make degradable composites
bioactive, inorganic components such as glasses, glass
ceramics, and calcium phosphates are often used to pro-
duce composites; the fillers act to enhance the mechanical
stiffness and strength as well as bioactivity.
The earliest biodegradable polymer composite was PHB
reinforced with HA. Doyle et al. [41] studied bioactive PHB
composite filled with HA; the modulus reached 11GPa at
40 vol% filler. In vivo studies showed that the stiffness
of the composite reduced to 5GPa after four months of
immersion in SBF and the degradation rate was con-
trolled by the composition and processing condition. There
was also no chronic inflammatory response reported after
12 months implantation, indicating that PHB has good
compatibility properties.
Solvent casting is a simple method to produce degrad-
able composites usually at room temperature and to
produce for simple shapes such as flat sheets. The polymer
is dissolved in an appropriate solvent at a concentration
to give a suitable viscosity. The solution is cast onto a
nonstick surface, such as glass, and allowed to dry slowly.
The film can be removed once the solvent has evaporated.
Composites are produced by mechanically mixing a filler
into the solution to produce good dispersion of the filler
and to prevent particle agglomeration. Misra et al. [42]
adopted this method to produce PHB reinforced with 5
or 20wt% Bioglass® 45S5. The addition of the Bioglass
powder reduced the tensile modulus; however, DMA test-
ing showed increases in the storage and loss moduli. It
was suggested that difference was due to dewetting of
Figure 2. Screws, washers, a pin, and plates made of forged and
then machined u-HA/PLLA composites. Source: From Shikinami
and Okuno [43].
the polymer–glass interface or agglomeration of the filler
particles, leading to premature failure of the composite
interface at higher stress levels than those used in DMA.
The composite also show bioactivity when soaked in SBF
solution.
Shikinami and Okuno [43] successfully produced
PLA/HA composites with strengths above that of cortical
bone. They synthesized their own HA particles and mixed
them into a PLLA/dichloromethane solution followed by
precipitation. The composite was processed via extrusion
and forging before it was finally machined into fracture
fixation devices (Fig. 2). Increasing the HA content
increases the modulus up to the maximum filler level of
50wt% HA with the bending strength reported of 270MPa
exceeding that of cortical bone and modulus up to 12GPa.
The bending strength remained above 200MPa for the
first 25 weeks in phosphate-buffered saline (PBS) solution;
thereafter, it was gradually decreased to 120MPa after
52 weeks (Fig. 3).
Wright-Charlesworth et al. [44,45] produced 0–40wt%
HA in PLLA using compounding extrusion and injection
molding. The addition of HA, as expected, increased the
stiffness, but at the same time, decreased the strength of
the PLLAwith less drawing of the polymermatrix between
the particles during the failure process. Soaking in PBS
solution at 37◦C showed that increasing the HA content
decreased the degradation rate. As with most degradable
composites, the strength seems to decrease faster than
stiffness for all compositions. The ideal fracture fixation
implant stiffness should reduce faster than the strength to
allow gradual load transfer from the implant to the healing
bone, while retaining strength to prevent refacture.
Melt spinning can produce PLLA fibers with tensile
strength and modulus up to 1800MPa and 9.3GPa,
respectively [46]. Solution spinning to manufacture PLLA
fibers can lead to 560–2300MPa tensile strength and
9.6–16GPa tensile modulus [47,48]. As with any other
fiber, these fibers can be used to increase the mechanical
properties of composites. To¨rma¨la¨ and colleagues used
high temperature and pressure to sinter PLLA fibers
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Figure 3. A schematic illustration of self-reinforced composite
consisting of matrix (m) reinforced with parallel reinforcing
lements (f). Source: From To¨rma¨la¨ et al. [49].
to produce a composite with reinforcing elements and
binding matrix with the same chemical composition.
To¨rma¨la¨ and colleagues [49–51] manufactured sintered
self-reinforced, absorbable polyglycolide (SR-PGA), and
injection molding PGA rods with 1.5–3.2mm diameter
presented bending moduli of 10–12 and 7GPa, respec-
tively. The bending strengths were 260 and 218MPa
with shear strengths of 192 and 95MPa, respectively.
Degradation studies also showed that the strength of
the specimens could be retained more than eight weeks.
These self-reinforced implants were developed through
to clinical application. However, the company developed
to exploit the fiber-reinforced composite technology has
subsequently concentrated on different PLA, PGA, and
trimethylene carbonate (TMC) copolymers.
Triphasic composites of PLA–PLA–TCPwere produced
with flexural strength of 65–80MPa and flexural modulus
more than 7GPa [52,53]. The composites were produced
by producing a prepreg of PLA96, that is, 96% PLLA, fibers
in a PLA70 (70% PLLA and 30% PLDLA) matrix that was
reinforced with HA or TCP. The strength was maintained
up to 12 weeks soaking in buffered saline and, thereafter,
lost stiffness and strength slowly. The presence of the
calcium phosphates also increased the bioactivity of the
materials when assessed by soaking in PBS solution and
also slowed the degradation, compared to PLLA/PLDLLA
composite prepared in the same manner, but without any
calcium phosphate. The pH also remained near neutral
for longer as the TCP degradation chemically buffered the
lactic acid produced as the PLA degraded and furthermore
slowed the degradation.
Bone Tissue Engineering Scaffolds
Until recently, materials were implanted into the body and
the body was required to provide cells to the new implant
surface. However, tissue engineering has been developed
where cells are taken, commonly from the patient’s own
body, seeded into a porous scaffold and allowed to grow
before being reimplanted back into the body [6]. The space
for in vitro cell growth allows faster cell division than in
the body and thus an increase in cell number. One of the
earliest applications was for cartilage defects where cells
are taken from a nonlead bearing area of joint cartilage
and expanded up and then replaced in a damaged load
bearing area of cartilage. Scaffolds are designed to boost
tissue repair rate by providing a large surface area to sup-
port revascularization, that is, restoration of the vascular
system to allow the supply of nutrients and removal of
waste products from the new tissue, and by integration of
the regenerating tissue within the system. A scaffold needs
to be open-celled porous with mechanical properties such
that the implant will not collapse either on implantation
or during use, until the newly formed tissue has taken over
the mechanical function of the implant. In the case of bone
tissue engineering, the scaffolds also need to be bioactive
in addition to the usual biocompatible requirement. There
are a range of methods to produce porous scaffolds such
as thermally induced phase separation (TIPS), solvent
casting with particulate leaching, sintering, microsphere
templating, and others.
TIPS can be used to produce scaffolds with very high
porosities up to 97% and very good pore interconnectivity
that are usually used for tissues such as nerve, muscle,
tendon, and ligament [54,55]. In this method, the poly-
mer is dissolved and glass or ceramic powder then added
into the polymer solution. For example, to produce high
porosity PLDLLA/Bioglass composite scaffolds, the mix-
ture was transferred into a flask and sonicated, followed
by quenching in liquid nitrogen for 2h at −196◦C. The
frozen mixture was later held at −10◦C; the solvent was
sublimated at −10◦C and then at 0◦C for 48h, followed
by drying at room temperature in a vacuum oven until
the weight is constant. Maquet and colleagues [54–58]
using the TIPS method successfully produced structure
with tubular macropores of 100 μm, interconnected with
micropores 10–50 μm in diameter. After adding 40wt%
Bioglass, the pore volume decreased from 9.5 to 5.7 cm3/g,
with no apparent change observed in the overall pore
morphology. Both the PLDLLA/Bioglass composites and
the unfilled PLDLLA foams maintained their structural
integrity up to 16 weeks.
Another method to produce scaffolds is by solvent cast-
ing and particle leaching. In addition to the solvent,
polymer, and filler particles, a further material is added
that is not soluble in the polymer solvent, but is soluble in
another liquid such as water, or can bemelted out, and this
material is known as the porogen. After the evaporation
of the polymer solvent, the porogen is removed, leaving
behind spaces previously occupied by the granules. Salt
and sugar are commonly used as they are easily obtained,
dissolve quickly in water, and any residuals are nontoxic.
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Figure 4. Typical morphologies of
porous polymer foams produced by
different techniques and structure
of cancellous bone: (a) Thermal
induced phase separation, (b) sol-
vent casting and particle leach-
ing, (c) cancellous bone, and (d)
microsphere—sintering. Source: Part
(a), from Maquet et al. [56]; part (b),
from Weng et al. [35]; part (c), from
Gibson [64]; part (d), from Lu et al.
[62].
(a) (b)
(c) (d)
Dunn et al. [59] used salt leaching to manufactured scaf-
folds of 10wt% HA in a blend of PCL and poly(DL-lactic
acid-co-glycolic acid) at 10:90 or 40:60 PCL: Degrada-
tion testing was performed in PBS and serum-containing
media, showing the pH decrease despite the present of HA
in the composite. In a study by Li and Chang [60], porous
scaffold of poly(β-hydroxybutyrate-co-β-hydroxyvalerate)
(PHBV) reinforced with 0–40wt% Wollastonite has been
produced with porosity between 73% and 80% using the
porogen method. The composite was found to be bioac-
tive when soaked in SBF and the contact angle decreased
with increasing amount of Wollastonite, making the mate-
rials to be more hydrophilic and thus increasing cell
attachment. Weng et al. [35] used sugar leaching to man-
ufacture porous scaffolds of PLLA reinforced with 20wt%
plasma-sprayed calcium phosphates. The spherical parti-
cles of CaP had smooth amorphous surfaces with crys-
talline cores. The surface layer dissolved easily when
soaked in SBF or after ultrasonication in distilled water.
The composite scaffold was expected to be highly bioactive
as the amorphous calcium phosphate dissolved and then
reprecipitated on the internal and external surfaces of
the scaffold, giving a large number of potential nucleation
sites on the scaffold surface.
Polymeric scaffolds also can be produced using a micro-
sphere sintering process. Microspheres of a ceramic and
polymer composite are synthesized using emulsion/solvent
evaporation technique, followed by sintering the com-
posite microspheres to produce 3D porous scaffolds. Lu
et al. [61–63] successfully produced 3D composites of
degradable polymers and BG using this method. First,
PLA–PGA copolymer (polylactide-co-glycolide, PLAGA)
Bioglass composite microspheres were produced through
a water–oil–water emulsion technique and then com-
pressed and heated to sinter the spheres together. This
resulted in an interconnected porous structure with an
average porosity of 40% with 90 μm pore diameter. The
mechanical properties reported were close to those of can-
cellous bone. Furthermore, cell culture studies show a
good response to the materials. This method was further
developed by Yao and colleagues [63] to produce porous 3D
scaffolds of PLGA/BG. They showed the materials have a
very good bioactivity response and promoting osteogenesis
of marrow stromal cells. Figure 4a,b and d shows vari-
ous typical microsphere-sintered 3D structure produced
by different methods in comparison to cancellous bone
(Fig. 4c).
MECHANICAL PROPERTY TESTING
Mechanical testing of biomedical composites uses the same
standards as composites for other applications. How-
ever, because of the cost of the materials, the size of
the samples is commonly reduced. Samples need to be
tested in both the ‘‘as produced’’ and ‘‘sterilized’’ that is
ready-to-use state. In addition, samples should be tested
after soaking in physiological solutions at 37◦C for vary-
ing times to give partially degraded samples, particularly
with degradable composites, although some changes have
been seen in nondegradable materials after soaking with
fluid intake, leading to some plasticization of the polymeric
phase. Among the standards tests performed are tensile,
compressive, impact, creep fatigue, and microhardness
testing. The results of typical tensile test studies have
been discussed throughout this article. The classic failure
mode of particulate-filled polymers has been described by
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Friedrich and Karsch [65] where debonding of the poly-
mer matrix from the filler surface is followed by drawing
of polymer fibrils between the filler particles. While their
studies were applied to tensile testing, the same failure
mode is also seen after impact, fatigue, and creep loading.
Dynamic mechanical analysis (DMA) including temper-
ature effects (DMTA) has been popular as small specimens
can be used and, with the costs and difficulties of produc-
ing biomedical composites, such studies have benefits. A
typical flexion DMA test sample is 1 × 2 × 23 mm3, while
compression samples are small cubes or cylinders a few
millimeters in height. Nazhat et al. [40,67–69] in a series
of studies used DMA to investigate the mechanical prop-
erties of different composites. In their first study [66], they
compared the storage modulus (E′) measured using DMA
with Young’s modulus (E) of HA/PE composites and found
a linear corrolation given by
E′ = 0.98E+ 0.95 (R2 = 0.996). (1)
In subsequent studies, Nazhat with various coauthors
investigated various composites developed by Bleach et al.
[53], Blaker et al. [69], and Misra et al. [42]. Zhang et al.
[70] used DMA to optimize the processing parameters for
selective laser-sintered HA in polyamide and showed that
for a given scan speed optimizing the laser power could
increase the modulus by a factor of 1.5 (Fig. 5a). In all
these DMTA studies, the transition temperatures seen for
the nonreinforced polymer are also seen in the composite
(Fig. 5b).
Younesi and Bahrololoom [71] studied the effect
of molecular weight, particle size, and Ringer’s solu-
tion on the impact properties of surface treated of
polypropylene-filled HA composite. Their samples were
notched Izod specimens of 64 × 10.2 × 6.4 mm3. About
6.4mm was used instead of the standard specimen
thickness of 3.2mm to give higher bending resistance.
Samples were tested both dry and after soaking in
Ringer’s solution for 30 days. Impact tests were carried
out using drop weight impact testing that was performed
by Zhang and Tanner [72,73] using 4-mm-thick 60mm
square samples, and they showed that increasing the
molecular weight from 50,000 to 250,000 increased the
total energy absorbed by a factor of 18 while adding 40
vol% spray-dried HA reduced the total energy absorbed
by a factor of 12. They further found that replacing the
spray-dried HA with a sintered HA with the same particle
size but one-tenth the specific surface area increased the
total energy absorbed by a factor between 1.5 and 2.0
depending on the volume fraction of filler.
The classic biomaterial to undergo fatigue testing is
bone cement, given that the major failure of bone cement
is due to the one million or so load cycles applied per year
[74]. Most bone cements are polymethylmethacrylate with
various amounts of fillers in the form of radiopacifiers
and antibiotics, and these are considered too low filler
concentrations to be described as a composite material.
Ton That et al. [75,76] studied the fatigue behavior of
HA-reinforced PE in fully reversed axial tension compres-
sion and fully reversed torsion using cylindrical dumbbell,
which were machined according to the ASTM E466 stan-
dard. Fatigue tests were then carried out using sinusoidal
loading at a frequency of 2Hz at various loading levels,
in saline solution at 37◦C. S–N curves were established,
showing that in tension–compression fatigue, the cycles
to failure range from 1000 cycles at ±13 MPa to more
than one million cycles at ±4.4 MPa. In torsion mode, the
fatigue cycles range from 100 cycles at 75% of the ultimate
shear stress to more than one million cycles for the 25% of
the ultimate shear stress loading level.
In general, polymers have poor creep resistance which
results in poor service life. Some of the early studies by
Suwanprateeb et al. [77–79] are on HA-reinforced HDPE.
While conventional creep testing is extremely time con-
suming, isochronous testing allows a large amount of
initial data to be collected [81]. Here, a small stress is
applied for a short time, say 100 s, the strain at the end
of this time is measured and then the stress is removed
for four times the original loading time (400 s); a higher
stress is applied for 100 s and again the strain is measured
at the end of the loading time. This load unload process
is applied for gradually increasing stress levels (Fig. 6a)
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Figure 5. DMA analysis of (a) of SLS HA–PE composite manufactured with powder size of either
<105 μm and >105 μm and laser power of 4.8 or 6.0W and (b) comparison of storage modulus of
fully dense and sintered HAPE, HAPA, and PA samples. Source: From Zhang et al. [38].
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Figure 6. Isochronous creep testing of HA PE composites showing (a) strain and stress variations
with time in isochronous testing, (b) the effect of adding 20 and 40 vol% HA to HDPE, and (c) the
effect of soaking 40 vol% HAPE for ◦ nonimmersed; • 7 days; * 30 days; ×90 days; and  150 days.
Source: From Suwanprateeb et al. [77,78].
and finally an isochronous stress–strain curve is plotted.
While allowing a large amount of data to be collected in a
relatively short time, isochronous testing also allows the
choice of the most appropriate stress levels for long-term
creep testing. Isochronous creep testing can also allow
various factors to be compared. They found that adding 20
and then 40 vol% HA halved the creep strain for a given
stress level (Fig. 6b). They showed that 40 vol% HA in PE
can sustain static tensile loads of up to 6MPa in saline
solution. The importance of soaking samples before testing
were considered by Suwanprateeb et al. [78] who showed
that despite the nondegradability of PE, soaking in saline
at 37◦C caused the absorption of 0.1wt% of liquid, which
had minimal effects on the creep behavior, whereas with
40 vol%HA 1wt% liquid was absorbed that nearly doubled
the isochronous creep strain for a given stress (Fig. 6c).
Younesi and Bahrololoom [80] studied the creep behav-
ior of the surface treated of polypropylene-filled HA com-
posited in Ringer’s solution. The samples were tested at
dry and wet conditions, which was soaking time for 30
days in Ringer’s solution. The test was carried out at 35%
of their corresponding ultimate tensile strength (UTS)
in physiological environment. They found that the creep
resistance increased by decreasing the HA particle size, as
this increased the contact surface between particles and
thematrix. The decrease in friction reduces themotion and
slippage between the polymers chains and thus reduces the
deformation between the matrices, resulting in stronger
composite. These findings are supported by Starkova et al.
[81], who reported that adding nanoparticles filler reduces
the strain in the primary as well as secondary creep
stage by restricting the movement of polymer chains, thus
producing higher creep resistance properties.
Degradation testing for the biodegradable composites is
most often carried out in the samemanner as nondegraded
composite. Bleach et al. [52] showed that after 10 weeks
soaking samples of PLLA fibers in a TCP/poly(L,DL-lactide)
matrix absorbed less water and showed less mass loss
than the samples prepared in the same manner but with-
out the TCP. They hypothesized that the presence of
the TCP chemically buffered the acid produced by the
breakdown of the PLA and thus slowed the degradation.
Kikuchi et al. [82] conducted three-point bending tests on
copolymerized PLLA (CPLA) and TCP/CPLA composites.
They reported that in the first four weeks of soaking in
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saline solution, bending strength of pure CPLA was con-
stant, but declines rapidly thereafter. Niemela¨ [83] used
shear testing to characterize self-reinforced poly-L-lactide
(SRPLA) and TCP/SRPLA composites after in vitro hydrol-
ysis. Results showed that all SRPLA rods retained their
initial shear strength virtually unchanged up to 30–36
weeks, but thereafter the composite strength decreased
rapidly. After 52 weeks of degradation testing, the com-
posite appeared to have 15% of initial shear strength in
comparison to TCP/SRPLA that managed to retain about
60–70% of the initial value. Kobayashi and Yamadi [84]
used conventional tensile testing to study the strain rate
dependency of mechanical properties of β-TCP/(PLLA).
They used rectangular specimens produced using injec-
tion molding technique and then immersed in SBF for
8, 16, and 24 weeks before testing. They found that the
modulus and strength increased with strain rate, but that
soaking reduced these increases.
Suwanprateeb et al. [85] used flexural testing to study
the influence of three-dimensional printing fabrication
technique for bioactive HA/bis-GMA (bisphenol A-glycidyl
methacrylate) based composite.
In the field of tissue engineering, among other param-
eters that need to be considered in scaffold fabrications
is that they should have appropriate and controllable
mechanical properties, for example, elastic constants and
compressive strength to provide sufficient temporary sup-
port for cells to enable tissue regeneration. Lu et al.
[86] developed a three-dimensional porous composite of
PLAGA and 45S5 BG (PLAGA–BG composite) scaffold for
bone tissue. Compression testing showed that adding the
BG granules to the composite yielded higher compressive
modulus than PLAGA alone. Blaker et al. [87] performed
similar compression testing to study the mechanical prop-
erties of highly porous PDLLA/Bioglass produced by TIPS
technique. Compression tests were performed axially and
transversely from 2 to 300kPa. They also used DMA to
establish the storage modulus (E′), loss modulus (E′′), and
mechanical loss tangent (tan δ). Results indicated that
mechanical anisotropy was controlled by the direction of
the macropores.
Microhardness studies, using a Vickers diamond
indenter, were carried out by Sousa and colleagues [32] to
investigate the structure development and interfacial
interaction of preferred orientation in HDPE/HA compos-
ite. In the latter study, they investigated the influence
of the processing on the mechanical performance of
HA-reinforced biodegradable starch-based blends and
HDPE [33].
IN VITRO BIOACTIVITY AND BIOCOMPATIBILTY TESTING
The biocompatibility of materials is an essential prop-
erty for their use inside or in contact with the human
body. Materials must to be nontoxic but should act as a
substrate to promote cell spreading and growth in cer-
tain applications, while in other applications, the surface
should prevent cell attachment. The second requirement
is bioactivity. In vitro bioactivity testing was initiated by
Kokubo et al. [7] who showed that materials that are bone
bioactive in vivo will develop a hydroxy-carbonate apatite
(HCA) layer when placed in a SBF, which has similar ion
levels as those of blood plasma. This work was extended
by Hench [88,89] who defined a bioactivity index based
on the inverse of the time to get the entire surface of
the biomaterial covered with an HCA layer (Fig. 7). Hench
compared various formulations of Bioglass particles to find
the highest bioactivity formulation. In composites work,
Huang et al. [90] used this technique to compare 20 and
40 vol% Bioglass in PE and showed that after seven days
the HCA layer had covered almost all the surface of the
composite, while with only 20 vol% Bioglass very little of
HCA layer has progressed beyond from the particles onto
the PE (Fig. 5). Maquet et al. [56] manufactured foams of
PDLLA reinforced with Bioglass particles as bone tissue
scaffolds. The in vitro bioactivity results showed the rate
of apatite deposition both on the surface and throughout
the foams increased with increasing Bioglass content. At
the same time, they also found some apatite deposition on
the nonfilled PDLLA foams.
In vitro evaluation of the biocompatibility usually pro-
vides initial screening often using cell lines tominimize the
variability in terms of metabolism, distribution, absorp-
tion and to maximize the cell response to possible toxicity
reaction that may have. The results of in vitro testing
of bioactive materials can indicate whether the material
increases the response of the cells to the material, that is,
it is bioactive as well as whether the material is biocom-
patible. Two types of cells are used: immortalized cell lines
are obtained from either malignant tumors or where a cell
line has been transformed and primary cells are obtained
(a) (b)
Figure 7. The formation of HCA
layers on (a) 20% and (b) 40% Bio-
glass/HDPE composite after seven
days in SBF. Source: From Huang
et al. [90].
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from people or animals and then grown up. The immor-
talized cells can be grown up and divided and grown up
again an infinite number of times (each step being called
a passage) so that they are convenient to use, but they
are pathological cells. In contrast, primary bone cells are
commonly harvested from discarded femoral heads after
hip replacement, and so are considered normal cells but
suffer from variability depending on age, gender, etc. of
the individual from which they are taken. Furthermore,
they can only be used for a limited number of passages
as they differentiate from their cell type after a number
of passages. A wide range of materials have been inves-
tigated both for bioactivity and biocompatibility; some of
these studies are described below.
Brauer and coworkers [91,92] produced a porous mate-
rial using a methacrylate-modified oligolactide polymer
network and phosphate-based glasses in the system
P2O5–CaO–MgO–Na2O–TiO2. These glasses were used
to reinforce 10wt% methacrylic acid 2-hydroxyethylester
(pHEMA) copolymer at ∼1:3.0 polymer-to-glass weight
ratio. The porous structure was produced through the
salt leaching method. In vitro cell culture testing was
carried out using the MC3T3-E1 osteoblast cell line.
They reported that the materials was nontoxic and
biocompatible.
The foams produced by Maquet et al. [56] were later
tested by Blaker et al. [93] in vitro cell culture using the
osteosarcoma (bone cancer) line MG-63 for up to eight
days. In cell culture studies, the osteosarcoma cells were
deposited on the outer layer of the foam. They reported
that the highest cell count was from 5wt% Bioglass foams,
but overall good attachment to the materials was found.
In vitro testing using three different cell lines,
macrophages, osteoblasts, and osteoclasts, were used to
study the biocompatibility of the PHBV composite filled
with 40–50wt% HA or TCP [94]. The three cell lines used
cover those cells that are involved in the inflammatory
response to materials, bone deposition, and bone resorp-
tion, respectively. The results showed that the addition of
bioactive calcium phosphates enhances the cell response.
In the macrophage study, they found low inflammatory
responses with the reinforced materials with a slightly
higher response with the nonfilled PHBV. The osteoblast
study, that is, using cells involved in bone deposition,
showed that plain HA or PHBV filled with HA produced
more calcium and more mineralization than unfilled
PHBV or when filled with TCP. In the osteoclast-like cells
study, the cells attached to the composite were seen to
be active but unable to resorpt the materials. In contrast,
resorption pits were observed on samples of bone.
IN VIVO BIOCOMPATIBILITY TESTING
Full in vivo biocompatibility testing involves tests such
as irritation, intracutaneous reactivity, systemic toxicity
(acute toxicity), subchronic toxicity, genotoxicity (affects
later generations), hemocompatibility (i.e., blood compati-
bility), chronic toxicity, carcinogeniticity (cancer causing),
biodegradation, and immune responses [2]. If an entirely
new material is developed, it will need to undergo the
full set of tests; however, for composite biomaterials, usu-
ally the individual component materials have been tested.
Therefore, for a composite that has undergone in vitro
testing, the in vivo test is usually to assess the response
to the material when in a body and under mechanical
loading. The in vivo study allows long-term investigation
of the biofunctionality in the complex biological environ-
ment before proceeding with clinical testing. As it involves
animal implantation testing, it has to comply all aspects
of legal rules and ethics on animal experimentation of the
country concerned.
Shikinmari and Okuno [43] successfully developed
high modulus HA/PLLA rods, which was later used by
Furukawa and colleagues [95,96] for in vivo testing in
rabbits both subcutaneously and in the femoral medullary
cavity. The HA was either calcined, to increase the
cystallinity, or noncalcined. The subcutaneous implan-
tation was used to observe the material’s degradation
behavior. After 52 weeks, the reduction of the molecular
weight was reported to be less than 10%; however,
the bending strength remained high enough to provide
sufficient mechanical support to the system. In their
second study, initial intermedullary implantation was
studied between 2 and 25 weeks. They reported a fibrous
layer surrounding the implants of nonreinforced PLLA,
while the reinforced composite exhibited bone contact by
two weeks and the amount of contact gradually increased.
More bone contact was observed in 40wt% than that in
30wt% HA composites and those composites filled with
the uncalcined HA. In the third paper [97], they reported
that after four years in vivo testing the diameter of the
rods has reduced to 77% of their original cross section.
While after six or seven years, in some sections there was
no material remaining; it was also observed that bone had
replaced the lost composite. In vivo studies very rarely
run beyond even one year because of the short life span
of rabbits; thus, over seven years in these studies are
probably unique.
Na¨rhi et al. [98] evaluated biological reaction to
the bioactive composite and the biologic behavior of a
poly(ε-caprolactone-co-DL-lactide) composite filled with 40
or 60wt% BG implanted in the long bones of rabbits for 8
and 16 weeks. In eight weeks, the implants were covered
with fibrous capsule and no direct contact with bone was
observed. After 16 weeks, the capsule had thinned in all
samples with bone ingrowth observed, indicating that
the materials is compatible with the bone tissue. Similar
findings were later reported by Ranne and coworkers [99]
when implanted in rat subcutaneous tissue.
A large animal model, the sheep, was used to test a tis-
sue engineering scaffold manufactured using supercritical
processing of a PLLA β-TCP composite with similar struc-
ture as that of cancellous bone [100]. The rationale for a
large animal model includes the fact that the mechanical
loading is more physiological. Histology and microcom-
puted tomography were used to assess the bone ingrowth
into the implant. Controls were an empty hole and porous
HA, and it was found that with the composite at 2 and
4 months, there was fibrous layer surrounding the com-
posite implant that was replaced with bone contact by 12
months, in comparison with the HA implant filled with
new bone more quickly.
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Figure 8. Comparison of healing after 12 weeks of radial bone defect: (a–c) with no implant
in defect, (d–f) with gelatin/nHAP/fibrin scaffold without rhBMP-2 in the defect, and (h–j)
gelatin/nHAP/fibrin scaffold with rhBMP-2 repaired the defect. Source: From Liu et al. [101].
Liu et al. [101] developed a hybrid scaffold of
gelatin/nanohydroxypatite (nHAP) by incorporating
human BMP-2 (rhBMP-2) to enhance bone regeneration.
Microscopy showed the scaffold to have 3D porous
structure and DNA assay test revealed that the structure
was noncytotoxic and could promote cell proliferation. In
vivo testing carried out in a rabbit model indicated good
healing of the skull defect after 12 weeks of implantation
(Fig. 8).
CLINICAL USES
As discussed earlier, the first clinical use of composites
was in the form of carbon-fiber-reinforced epoxy resin as
facture fixation plates [15–17].While Downes et al. [21,22]
used HA/HDPE composite for orbital floor implants and
this material then progressed to extensive use in the shaft
of middle ear implants as HAPEX [23,24]. Since 1990,
the numbers of publications on fracture fixation in the
human hand using bioabsorbable devices have increased.
SR-PLLA pins (diameter 1.5 or 2.0mm) [104] were used
in clinical studies for the fixation of small fragment frac-
tures and osteotomies. It was reported that in 27 patients,
uneventful recovery of the function was accomplished in
four fractures of the metacarpal and three of the proximal
phalanx [103]. Arata et al. [102] reported that in 26 cases
of digital replantation using intramedullary SR-PLLA
rods, no cases of nonunion or infection occurred. How-
ever, in one patient transient bone resorption occurred.
They summarized that the intramedullary bioabsorbable
rods gave stable, simple, and effective osteosynthesis in
digital replantation. Bioabsorbable pins and screws can
be used to stabilize fusions. Rokkanen et al. [106] wrote
that in rheumatoid arthritis patients, bioabsorbable poly-
mers (such as PLLA) with slow degradation are preferred.
SR-PLLA pins with cross section of 1.5–2.0mm were
observed to provide stable fixation for 18 interphalangeal,
metacarpophalangeal, and carpometacarpal arthrodeses
when tested in patients with rheumatoid arthritis [104].
No complications were observed and the authors concluded
Figure 9. Macropore bioabsorbable sheet and screw of 70:30
PLLDLA polymer. Source: From Park et al. [104].
that the results were comparable with earlier studies on
use of metal implants. Furthermore, in the same study, 18
wrist jointswere fused uneventfullywith 3.2mmSR-PLLA
pins and only one patient reported a superficial infection
postoperatively.
Park et al. [105] evaluated the clinical use of PLDLLA
70:30 bioresorbable implants in the cervical spine, that is,
the neck (Fig. 9). The deviceswere implanted in 26 patients
with an average age of 50.7 years. The patients underwent
fusion one or two invertebral discs with allograft and fitted
with 1-mm-macropore bioabsorbable plate and screws and
followed up for up to two years. At average 14 months
after the surgery, 96.2% of the patients achieved good
radiographic fusion with no apparent sign of soft tissue
reaction. Vacarro et al. [106] used the same plate and
screw on nine patients with degenerative and traumatic
disc herniations. In 77% patients, a solid fusion was seen
when radiographically examined after six months. Clinical
evaluation was repeated at 32 months of follow-up, and
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Figure 10. Self-reinforced poly-L-lactide (SR-PLLA) and
self-reinforced poly-L/DL-lactide (SR-P(L/DL)LA) miniplates, pins
(diameter 1.5, 2.0, and 3.2mm), tacks, and screws (diameter 2.0
and 1.5mm) for bone fixation in the hand. Source: From Waris
et al. [107].
no soft tissue inflammatory or clinical complications were
recorded.
Composites have been developed that have been used
in patients since the 1970s; the early composites, such
as carbon-reinforced epoxy [15–17], were used in a few
patients and then were either too complex to use or had
insufficient advantages over similar devices manufactured
of more conventional metal implants. One composite mate-
rial, HAPEX, did enter extensive clinical use but owing to
lowmechanical properties could only be used in the orbital
floor or middle ear implants. However, it did show that
the use of composites allowed bioactivity to be combined
with the ductility of polymeric phases.
The conventional composite production techniques such
as the development of prepregs and then compression
molding have been applied to biomaterials and have
allowed the production of composites with higher mechan-
ical properties [49–53]. Self-reinforced PLA composites
have entered extensive clinical use (Fig. 10).
The latest developments in composites are as bioactive
scaffolds for bone tissue engineering. There are a series of
new composites under development and in various stages
of testing from in vitro through to clinical trials. It is hoped
that in the next few years some of these will come into
general use.
Composites based on the application of conventional
materials production techniques to biologically compat-
ible materials have been used since the 1970s. Their
application is gradually increasing because of the bene-
fits of modulus compatibility with the materials they are
replacing and the bioactivity of the some of the individ-
ual materials used in the composite manufacture. Both
degradable and nondegradable materials can be manufac-
tured depending on the starter materials. Optimization of
the filler content and processing regime should be used
to optimize both the mechanical and biological proper-
ties. The applications can run from low modulus porous
degradable scaffolds containing bioactive molecules used
for tissue engineering to high modulus (for a composite)
nondegradable implants allowing to permanently replace
a lightly load bearing bone. Currently, no composite mate-
rial has been used successfully to replace a major load
bearing bone, but that is only a matter of time.
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